These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 36290010)

  • 1. In vitro Activity of Cefiderocol and Comparators against Carbapenem-Resistant Gram-Negative Pathogens from France and Belgium.
    Oueslati S; Bogaerts P; Dortet L; Bernabeu S; Ben Lakhal H; Longshaw C; Glupczynski Y; Naas T
    Antibiotics (Basel); 2022 Oct; 11(10):. PubMed ID: 36290010
    [TBL] [Abstract][Full Text] [Related]  

  • 2.
    Shortridge D; Streit JM; Mendes R; Castanheira M
    Microbiol Spectr; 2022 Apr; 10(2):e0271221. PubMed ID: 35262394
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    Naas T; Lina G; Santerre Henriksen A; Longshaw C; Jehl F
    JAC Antimicrob Resist; 2021 Jun; 3(2):dlab081. PubMed ID: 34223140
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Global prevalence of cefiderocol non-susceptibility in Enterobacterales, Pseudomonas aeruginosa, Acinetobacter baumannii, and Stenotrophomonas maltophilia: a systematic review and meta-analysis.
    Karakonstantis S; Rousaki M; Vassilopoulou L; Kritsotakis EI
    Clin Microbiol Infect; 2024 Feb; 30(2):178-188. PubMed ID: 37666449
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro activity of cefiderocol and comparators against Gram-negative bacterial isolates from a series of surveillance studies in England: 2014-2018.
    Gant V; Hussain A; Bain M; Longshaw C; Henriksen AS
    J Glob Antimicrob Resist; 2021 Dec; 27():1-11. PubMed ID: 34329792
    [TBL] [Abstract][Full Text] [Related]  

  • 6.
    Longshaw C; Manissero D; Tsuji M; Echols R; Yamano Y
    JAC Antimicrob Resist; 2020 Sep; 2(3):dlaa060. PubMed ID: 34223017
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro activity of cefiderocol and comparators against isolates of Gram-negative bacterial pathogens from a range of infection sources: SIDERO‑WT‑2014-2018 studies in Spain.
    Cercenado E; Cardenoso L; Penin R; Longshaw C; Henriksen AS; Pascual A
    J Glob Antimicrob Resist; 2021 Sep; 26():292-300. PubMed ID: 34274538
    [TBL] [Abstract][Full Text] [Related]  

  • 8.
    Karlowsky JA; Hackel MA; Takemura M; Yamano Y; Echols R; Sahm DF
    Antimicrob Agents Chemother; 2022 Feb; 66(2):e0199021. PubMed ID: 34807757
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activity of cefiderocol against high-risk clones of multidrug-resistant Enterobacterales, Acinetobacter baumannii, Pseudomonas aeruginosa and Stenotrophomonas maltophilia.
    Delgado-Valverde M; Conejo MDC; Serrano L; Fernández-Cuenca F; Pascual Á
    J Antimicrob Chemother; 2020 Jul; 75(7):1840-1849. PubMed ID: 32277821
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of In Vitro Activity of Cefiderocol Against Carbapenem-Resistant Gram-Negative Bacilli by Broth Microdilution and Disk Diffusion Method: A Single-Center Study in Odisha, India.
    Nayak G; Behera B; Mohanty S; Kar P; Jena J
    Infect Drug Resist; 2022; 15():5887-5897. PubMed ID: 36237292
    [TBL] [Abstract][Full Text] [Related]  

  • 11.
    Hackel MA; Tsuji M; Yamano Y; Echols R; Karlowsky JA; Sahm DF
    Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29158270
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro activity of the novel siderophore cephalosporin, cefiderocol, in Gram-negative pathogens in Europe by site of infection.
    Candel FJ; Santerre Henriksen A; Longshaw C; Yamano Y; Oliver A
    Clin Microbiol Infect; 2022 Mar; 28(3):447.e1-447.e6. PubMed ID: 34298176
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cefiderocol Antimicrobial Susceptibility Testing Considerations: the Achilles' Heel of the Trojan Horse?
    Simner PJ; Patel R
    J Clin Microbiol; 2020 Dec; 59(1):. PubMed ID: 32727829
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Susceptibility of cefiderocol and other antibiotics against carbapenem-resistant, Gram-negative bacteria.
    Wang Y; Li Y; Zhao J; Guan J; Ni W; Gao Z
    Ann Transl Med; 2022 Mar; 10(5):261. PubMed ID: 35402576
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro activity of cefiderocol and other newly approved antimicrobials against multi-drug resistant Gram-negative pathogens recovered in intensive care units in Spain and Portugal.
    Gijón D; García-Castillo J; Fernández-López MC; Bou G; Siller M; Calvo-Montes J; Pitart C; Vila J; Torno N; Gimeno C; Cruz H; Ramos H; Mulet X; Oliver A; Ruiz-Garbajosa P; Canton R
    Rev Esp Quimioter; 2024 Feb; 37(1):69-77. PubMed ID: 37882320
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.
    Zhanel GG; Golden AR; Zelenitsky S; Wiebe K; Lawrence CK; Adam HJ; Idowu T; Domalaon R; Schweizer F; Zhanel MA; Lagacé-Wiens PRS; Walkty AJ; Noreddin A; Lynch Iii JP; Karlowsky JA
    Drugs; 2019 Feb; 79(3):271-289. PubMed ID: 30712199
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In Vitro Activity of Cefiderocol, a Siderophore Cephalosporin, Against Gram-Negative Bacilli Isolated by Clinical Laboratories in North America and Europe in 2015-2016: SIDERO-WT-2015.
    Karlowsky JA; Hackel MA; Tsuji M; Yamano Y; Echols R; Sahm DF
    Int J Antimicrob Agents; 2019 Apr; 53(4):456-466. PubMed ID: 30471402
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro antibacterial activities of cefiderocol against Gram-negative clinical strains isolated from China in 2020.
    Kohira N; Hackel MA; Oota M; Takemura M; Hu F; Mizuno H; Sahm DF; Yamano Y
    J Glob Antimicrob Resist; 2023 Mar; 32():181-186. PubMed ID: 36513320
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Surveillance of In Vitro Activity of Cefiderocol Against Carbapenem-Resistant Gram-Negative Clinical Isolates in a Tertiary Care Hospital.
    Kammineni C; Vamsi S; Basireddy SR
    Cureus; 2024 Aug; 16(8):e67164. PubMed ID: 39161549
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro activity of cefiderocol against clinically important carbapenem non-susceptible Gram-negative bacteria from Saudi Arabia.
    Alzayer M; Alghoribi MF; Alalwan B; Alreheli A; Aljohani S; Bosaeed M; Doumith M
    J Glob Antimicrob Resist; 2023 Mar; 32():176-180. PubMed ID: 36481491
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.